Market closedNon-fractional
Veru/VERU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Veru
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Ticker
VERU
Sector
Consumer Non-Cyclicals
Trading on
NASDAQ
Industry
Personal Care Products
Headquarters
Miami, United States
Employees
189
Website
verupharma.com
Veru Metrics
BasicAdvanced
$139M
Market cap
-
P/E ratio
-$0.37
EPS
-0.47
Beta
-
Dividend rate
Price and volume
Market cap
$139M
Beta
-0.47
Financial strength
Current ratio
4.718
Quick ratio
3.922
Long term debt to equity
26.627
Total debt to equity
28.73
Interest coverage (TTM)
-16.92%
Management effectiveness
Return on assets (TTM)
-40.76%
Return on equity (TTM)
-125.82%
Valuation
Price to revenue (TTM)
7.477
Price to book
3.08
Price to tangible book (TTM)
3.63
Price to free cash flow (TTM)
-2.528
Growth
Revenue change (TTM)
-36.67%
Earnings per share change (TTM)
-78.21%
3-year revenue growth (CAGR)
-35.41%
3-year earnings per share growth (CAGR)
279.25%
What the Analysts think about Veru
Analyst Ratings
Majority rating from 5 analysts.
Veru Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$4.1M
95.24%
Net income
-$10M
21.95%
Profit margin
-243.90%
-37.54%
Veru Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
$0.07
-$0.12
-$0.08
-$0.07
-
Expected
-$0.21
-$0.24
-$0.10
-$0.05
-$0.06
Surprise
-134.15%
-48.94%
-22.58%
31.25%
-
Veru News
AllArticlesVideos
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
GlobeNewsWire·4 weeks ago
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
GlobeNewsWire·1 month ago
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veru stock?
Veru (VERU) has a market cap of $139M as of July 27, 2024.
What is the P/E ratio for Veru stock?
The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of July 27, 2024.
Does Veru stock pay dividends?
No, Veru (VERU) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Veru dividend payment date?
Veru (VERU) stock does not pay dividends to its shareholders.
What is the beta indicator for Veru?
Veru (VERU) has a beta rating of -0.47. This means that it has an inverse relation to market volatility.
Buy or sell Veru stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.